Pilose antler peptide attenuates high-fat-diet-induced liver injury

References

• Chatrath H, Vuppalanchi R, Chalasani N. 2012. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 32:22.
   PubMed Web of Science ®Google Scholar
• Chen Q, Wang T, Li J, Wang S, Qiu F, Yu H, Zhang Y, Wang T. 2017. Effects of natural products on fructose-induced nonalcoholic fatty liver disease (NAFLD). Nutrients. 9:96.
   PubMed Web of Science ®Google Scholar
• Chen W, Wang X, Huang LI, Liu BO. 2016. Hepcidin in non-alcoholic fatty liver disease regulated by the TLR4/NF-κB signaling pathway. Exp Ther Med. 11:73.
   PubMed Web of Science ®Google Scholar
• Elmakki E, Hussein H, Ibrahim B, Husam O, Yahya S, Asim T, Talal HM, Musa M, Saif EA, Mohamed M. 2015. Nonalcoholic fatty liver disease (NAFLD) in Saudi patients with T2DM in Jazan region: prevalence and associated factors. Br J Med Med Res. 5:872–879.
   Google Scholar
• Fan X, et al. 2016. Study on the relationship between different patterns of nonalcoholic fatty liver disease and the levels of TNF-α and IL-6. West J Trad Chinese Med.
   Google Scholar
• Hendy OM, Elsabaawy MM, Aref MM, Khalaf FM, Oda AMA, El Shazly HM. 2017. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease. APMIS. 125:607–613.
   PubMed Web of Science ®Google Scholar
• Kang KR, Lee M-S, Jung Y-U, Choi A-R, Han D-G, Kang A-H, Song W-S, Lee H-C, Um G-H. 2016. A case report of adolescent nonalcoholic fatty liver disease (NAFLD) with obesity. J Int Korean Med. 37:726–732.
   Google Scholar
• Lin J, Zhang Y, Wang X, Wang W. 2015. Lycium ruthenicum extract alleviates high-fat diet-induced nonalcoholic fatty liver disease via enhancing the AMPK signaling pathway. Mol Med Rep. 12:3835.
   PubMed Web of Science ®Google Scholar
• Lin TH, Yen HR, Chiang JH, Sun MF, Chang HH, Huang ST. 2017. The use of Chinese herbal medicine as an adjuvant therapy to reduce incidence of chronic hepatitis in colon cancer patients: a Taiwanese population-based cohort study. J Ethnopharmacol. 202:225.
   PubMed Web of Science ®Google Scholar
• Liu G, Ma C, Wang P, Zhang P, Qu X, Liu S, Zhai Z, Yu D, Gao J, Liang J, et al. 2017. Pilose antler peptide potentiates osteoblast differentiation and inhibits osteoclastogenesis via manipulating the NF-κB pathway. Biochem Biophys Res Commun. 491:388.
   PubMed Web of Science ®Google Scholar
• Ma Z, Chu L, Liu H, Wang W, Li J, Yao W, Yi J, Gao Y. 2017. Beneficial effects of paeoniflorin on non-alcoholic fatty liver disease induced by high-fat diet in rats. Sci Rep. 7:44819.
   PubMed Web of Science ®Google Scholar
• Mendes FD, Suzuki A, Sanderson SO, Lindor KD, Angulo P. 2012. Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 10:1028–1033.
   PubMed Web of Science ®Google Scholar
• Mittal S, White DL, Kanwak F, Sussman N, El-Serag HB. 2015. Nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma: how common? Curr Hepatology Rep. 14:87–98.
   Google Scholar
• Miura K, Seki E, Ohnishi H, Brenner DA. 2010. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2010:70–80.
   Google Scholar
• Peng Z, Gong X, Yang Y, Huang L, Zhang Q, Zhang P, Wan R, Zhang B. 2017. Hepatoprotective effect of quercetin against LPS/d-GalN induced acute liver injury in mice by inhibiting the IKK/NF-κB and MAPK signal pathways. Int Immunopharmacol. 52:281–289.
   PubMed Web of Science ®Google Scholar
• Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ, Steinberg GR. 2016. Treatment of non-alcoholic fatty liver disease (NAFLD): role of AMPK. Am J Physiol Endocrinol Metab. 311:E730–E740.
   PubMed Web of Science ®Google Scholar
• Tian Y, Ma J, Wang W, Zhang L, Xu J, Wang K, Li D. 2016. Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver. Mol Cell Biochem. 422:1–10.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR, Szabo G. 2016. Interleukin‐1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 64:955.
   PubMed Web of Science ®Google Scholar
• Trasino SE, Tang XH, Jessurun J, Gudas LJ. 2016. A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease. J Mol Med (Berl). 94:1143–1151.
   PubMed Web of Science ®Google Scholar
• Xin Y, Wei J, Chunhua M, Danhong Y, Jianguo Z, Zongqi C, Jian-An B. 2016. Protective effects of Ginsenoside Rg1 against carbon tetrachloride-induced liver injury in mice through suppression of inflammation. Phytomedicine. 23:583–588.
   PubMed Web of Science ®Google Scholar
• Xing LJ, Zhang L, Liu T, Hua YQ, Zheng PY, Ji G. 2011. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur J Pharmacol. 668:467.
   PubMed Web of Science ®Google Scholar
• Yang C, Gong X, Ai Q, Ge P, Lin L, Zhang L. 2015. 5-Aminoimidazole-4-carboxamide-1-β-d-ribofuranoside alleviated carbon tetrachloride-induced acute hepatitis in mice. Int Immunopharmacol. 25:393.
   PubMed Web of Science ®Google Scholar
• Yang Y, Bai T, Yao YL, Zhang DQ, Wu YL, Lian LH, Nan JX. 2016. Upregulation of SIRT1-AMPK by thymoquinone in hepatic stellate cells ameliorates liver injury. Toxicol Lett. 262:80–91.
   PubMed Web of Science ®Google Scholar
• Yin M, Talwalkar JA, Glaser KJ, Venkatesh SK, Chen J, Manduca A, Ehman RL. 2011. Dynamic postprandial hepatic stiffness augmentation assessed with MR elastography in patients with chronic liver disease. AJR Am J Roentgenol. 197:64.
   PubMed Web of Science ®Google Scholar
• Zhang ZQ, Zhang Y, Wang BX, Zhou HO, Wang Y, Zhang H. 1992. Purification and partial characterization of anti-inflammatory peptide from pilose antler of Cervus nippon Temminck. Yao Xue Xue Bao. 27:321.
   PubMedGoogle Scholar